Eric Luehr1, Gary Grone1, Manoj Pathak2, Cindy Austin3, Simon Thompson3. 1. Mercy Hospital-Springfield, Department of Trauma ServicesSpringfield, MO, USA. 2. Murray State University, Department of Mathematics & StatisticsMurray, KY, USA. 3. Mercy Hospital-Springfield, Trauma & Burn ResearchSpringfield, MO, USA.
Abstract
BACKGROUND: Since 2010, the use of Tranexamic Acid (TXA) in trauma has been brought to the forefront of severe hemorrhage treatment. However, the mixed literature illustrates the need for additional proof of efficacy and determining which patients may benefit from TXA. The purpose of this retrospective study was to evaluate a more stringent TXA inclusion criterion (heart rate ≥ 120 beats per minute (BPM) with a systolic blood pressure (SBP) ≤ 90 mmHg) as compared to the standard CRASH-2 inclusion criteria. METHODS: From 2013-2016 a total of 115 patients (control, n = 62; TXA, n = 53) were included in the analysis. These patients adhered to the standard CRASH-2 and more stringent inclusion criteria; they also survived at least 8.5 hrs (minimum amount of time required for full TXA dose) from the initiation. Basic characteristics of the patients were summarized. The mortality rates between TXA and control groups were compared using two proportion z-tests. All p values <0.05 were considered statistically significant. RESULTS: There was no statistical significant difference in patient characteristics between the two treatment groups, making them more comparable (p value >0.05). This study found a significant reduction of percent mortality at the 24 hr time point against the control (p = 0.007). Additionally, utilizing the more strict inclusion criteria (BPM ≥ 120 and SBP ≤ 90) substantially extended time to stabilize patients to 48 hrs (p = 0.029). CONCLUSION: By imposing the more strict criteria, TXA appears to be a better treatment option in reducing mortality rates and potentially extends the treatment time-frame for stabilizing the patient up to 48 hours.
BACKGROUND: Since 2010, the use of Tranexamic Acid (TXA) in trauma has been brought to the forefront of severe hemorrhage treatment. However, the mixed literature illustrates the need for additional proof of efficacy and determining which patients may benefit from TXA. The purpose of this retrospective study was to evaluate a more stringent TXA inclusion criterion (heart rate ≥ 120 beats per minute (BPM) with a systolic blood pressure (SBP) ≤ 90 mmHg) as compared to the standard CRASH-2 inclusion criteria. METHODS: From 2013-2016 a total of 115 patients (control, n = 62; TXA, n = 53) were included in the analysis. These patients adhered to the standard CRASH-2 and more stringent inclusion criteria; they also survived at least 8.5 hrs (minimum amount of time required for full TXA dose) from the initiation. Basic characteristics of the patients were summarized. The mortality rates between TXA and control groups were compared using two proportion z-tests. All p values <0.05 were considered statistically significant. RESULTS: There was no statistical significant difference in patient characteristics between the two treatment groups, making them more comparable (p value >0.05). This study found a significant reduction of percent mortality at the 24 hr time point against the control (p = 0.007). Additionally, utilizing the more strict inclusion criteria (BPM ≥ 120 and SBP ≤ 90) substantially extended time to stabilize patients to 48 hrs (p = 0.029). CONCLUSION: By imposing the more strict criteria, TXA appears to be a better treatment option in reducing mortality rates and potentially extends the treatment time-frame for stabilizing the patient up to 48 hours.
Authors: Evan J Valle; Casey J Allen; Robert M Van Haren; Jassin M Jouria; Hua Li; Alan S Livingstone; Nicholas Namias; Carl I Schulman; Kenneth G Proctor Journal: J Trauma Acute Care Surg Date: 2014-06 Impact factor: 3.313
Authors: Anthony E Pusateri; Richard B Weiskopf; Vikhyat Bebarta; Frank Butler; Ramon F Cestero; Irshad H Chaudry; Virgil Deal; Warren C Dorlac; Robert T Gerhardt; Michael B Given; Dan R Hansen; W Keith Hoots; Harvey G Klein; Victor W Macdonald; Kenneth L Mattox; Rodney A Michael; Jon Mogford; Elizabeth A Montcalm-Smith; Debra M Niemeyer; W Keith Prusaczyk; Joseph F Rappold; Todd Rassmussen; Francisco Rentas; James Ross; Christopher Thompson; Leo D Tucker Journal: Shock Date: 2013-02 Impact factor: 3.454
Authors: Jeremy G Perkins; Andrew P Cap; Brendan M Weiss; Thomas J Reid; Charles D Bolan; Charles E Bolan Journal: Crit Care Med Date: 2008-07 Impact factor: 7.598
Authors: Ian Roberts; Pablo Perel; David Prieto-Merino; Haleema Shakur; Tim Coats; Beverley J Hunt; Fiona Lecky; Karim Brohi; Keith Willett Journal: BMJ Date: 2012-09-11
Authors: Péter Jávor; Lilla Hanák; Péter Hegyi; Endre Csonka; Edina Butt; Tamara Horváth; István Góg; Anita Lukacs; Alexandra Soós; Zoltán Rumbus; Eszter Pákai; János Toldi; Petra Hartmann Journal: BMJ Open Date: 2022-10-19 Impact factor: 3.006